Marbocyl p 20 mg

Marbocyl is indicated for the treatment of skin and soft tissue infections (skin fold

pyoderma, impetigo, folliculitis, furunculosis, cellulitis), for the treatment of urinary tract

infections associated or not with prostatitis and respiratory tract infections, caused by

susceptible strains of organisms.

Ingredients: Marbocyl P 20 mg containing 20 mg marbofloxacin. For use in dogs and cats.

Dosage: The recommended dose rate is 2 mg/kg per day in a single daily administration. In

dogs for the treatment of skin and soft tissue infections, treatment duration is at least five days.

Depending on the course of the disease it may be extended up to 40 days. In urinary tract

infections, treatment duration is at least 10 days. Depending on the course of the disease it may

be extended up to 28 days. In respiratory infections, treatment duration is at least 7 days and,

depending on the course of the disease, may be extended up to 21 days. In cats for the

treatment of skin and soft tissue infections, treatment duration is 3–5 days. For upper respiratory

infections, treatment duration is 5 days.

Contra-indications: Marbofloxacin should not be used in dogs aged less than 12 months or

less than 18 months for exceptionally large breeds of dogs, such as Great Danes, Briard,

Bernese, Bouvier and Mastiffs with a longer growth period. Not recommended for use in cats

aged less than 16 weeks. Not suitable for infections resulting from strict anaerobes, yeast or

fungi. The fluoroquinolones have been shown to induce erosion of articular cartilage in juvenile

dogs and care should be taken to dose accurately, especially in young animals. The

fluoroquinolones are known for their potential neurological side effects; cautious use is

recommended in dogs and cats diagnosed as suffering from epilepsy. A low urinary pH could

have an inhibitory effect on the activity of Marbofloxacin. Mild side effects such as vomiting,

softening of faeces, modification of thirst or transient increase in activity may occasionally occur.

These signs cease spontaneously after treatment and do not necessitate cessation of the

treatment. At the therapeutic recommended dosage no severe side effects are to be expected.